Evans T J, Carpenter A, Moyes D, Martin R, Cohen J
Department of Infectious Diseases and Bacteriology, Royal Postgraduate Medical School, London, United Kingdom.
J Infect Dis. 1995 Jan;171(1):153-60. doi: 10.1093/infdis/171.1.153.
Bactericidal/permeability-increasing protein (BPI) has bactericidal properties and also binds lipopolysaccharide (LPS). The ability of a recombinant amino-terminal fragment of BPI to protect mice from death after challenge with a number of different strains of Escherichia coli was tested. BPI prevented death in animals challenged with the J5 rough strain but not with smooth strains O111:B4 and O7K1. Protection was associated with a reduction in serum LPS and tumor necrosis factor-alpha levels but not with reduction in blood bacterial counts. BPI was effective at protecting against death in mice injected with purified O111:B4 LPS. Lack of protection after injection with live O111:B4 and O7K1 may be due to production by these models of approximately 1000-fold higher blood bacterial count compared with J5. Thus, BPI is a promising therapy in the treatment of gram-negative septic shock, although the range of organisms against which it is effective remains to be determined.
杀菌/通透性增加蛋白(BPI)具有杀菌特性,还能结合脂多糖(LPS)。对BPI重组氨基末端片段在用多种不同大肠杆菌菌株攻击后保护小鼠免于死亡的能力进行了测试。BPI可防止用J5粗糙菌株攻击的动物死亡,但对光滑菌株O111:B4和O7K1无效。保护作用与血清LPS和肿瘤坏死因子-α水平降低有关,但与血液细菌计数降低无关。BPI对注射纯化O111:B4 LPS的小鼠有保护作用,可防止其死亡。注射活的O111:B4和O7K1后缺乏保护作用可能是因为与J5相比,这些模型产生的血液细菌计数高出约1000倍。因此,BPI在治疗革兰氏阴性败血症性休克方面是一种有前景的疗法,尽管其有效对抗的生物体范围仍有待确定。